SCHEMBL30768912

SCHEMBL30768912

CC(C)(C)OC(=O)N1CC[C@@]2(CCN(c3ccc(N4CCC(=O)NC4=O)cc3)C2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.46
▸ CYP3A4 P08684 6/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ DDB1 Q16531 5/20 0.43
▸ CRBN Q96SW2 5/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ SCD5 Q86SK9 1/20 0.43
▸ USP2 O75604 3/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HSD17B10 Q99714 2/20 0.41
▸ ACACB O00763 2/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HDAC2 Q92769 2/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ TNKS O95271 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30724065 0.95 CYP11B2 (0.49) CYP11B2CYP3A4CYP2C19DDB1CRBN
SCHEMBL31306782 0.94 CYP3A4 (0.48) CYP11B2CYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL22119507 0.83 DDB1 (0.59) CYP2C19TSHRDDB1CRBNALDH1A1
SCHEMBL2886266 0.83 CYP11B2 (0.52) CYP11B2CYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL4303345 0.83 CYP11B2 (0.52) CYP11B2CYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL30768730 0.82 CYP11B2 (0.46) CYP11B2DDB1CRBNSCD5ACACB
SCHEMBL20842160 0.82 GPR119 (0.57) CYP11B2CYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL25632150 0.81 DDB1 (0.49) DDB1CRBNALDH1A1
SCHEMBL30768423 0.81 CRBN (0.57) CYP11B2CYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL21963775 0.81 CYP11B2 (0.52) CYP11B2CYP3A4CYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-12-25 — — US disclosed
EP-4543871-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-04-30 — — EP disclosed
WO-2024006781-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF ESRRA, ESRRB, ESR2 CYP11B2 138/4885CYP3A4 672/4885CYP2C9 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback